WebDisclosure WebDisclosure
Basculer en Français
8692 Companies
150296 Keywords
85840 Articles
80593 Press releases
Headlines Articles Press releases POP Biotechnologies, Inc. Remove
  1. Home
  2. Companies
  3. POP Biotechnologies, Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 09/27/2024 at 20:05, 8 months 1 day ago

    POP Biotechnologies Announces Positive Interim Results for COVID-19 Vaccine Trial

    COVID-19 Vaccine Phase 3 Trial Immunogenicity EuCorVac-19 POP BIO SNAP
  • BRIEF

    published on 09/27/2024 at 20:05, 8 months 1 day ago

    POP Biotechnologies annonce des résultats intermédiaires positifs pour l'essai d'un vaccin contre la COVID-19

    Vaccin Contre Le Covid-19 Essai De Phase 3 EuCorVac-19 POP BIOGRAPHIE INSTANTANÉE Immunogénicité
  • PRESS RELEASE

    published on 09/27/2024 at 20:00, 8 months 1 day ago

    POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)

    POP Biotechnologies and EuBiologics announce positive findings of ECV-19 COVID-19 vaccine in Phase 3 trial in the Philippines, demonstrating safety, immunogenicity, and potential against Omicron variant
    COVID-19 Vaccine Phase 3 Trial POP Biotechnologies EuBiologics ECV-19
  • PRESS RELEASE

    published on 07/14/2023 at 18:00, 1 year 10 months ago

    POP Biotechnologies and EuBiologics' EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial

Accesswire
  • Published on 05/29/2025 at 15:00, 1 hour 43 minutes ago

    Elvictor Group Reports Strong Growth in Seafarer Deployment and Client Base, Projects Significant Expansion in 2025

  • Published on 05/29/2025 at 15:00, 1 hour 43 minutes ago

    E-Cite Motors Approved for Upgrade to OTCID Tier - Ticker Symbol to Transition to (OTCID:VAPR) on July 1st, 2025

  • Published on 05/29/2025 at 14:30, 2 hours 13 minutes ago

    NV Gold Announces Drill Program at the Slumber Gold Project in Nevada

  • Published on 05/29/2025 at 14:30, 2 hours 13 minutes ago

    Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

  • Published on 05/29/2025 at 14:00, 2 hours 43 minutes ago

    GameSquare's Stream Hatchet Redefines Gaming Analytics with Breakthrough AI-Powered Data Ecosystem

View all ACCESSWIRE
EQS Group
  • Published on 05/29/2025 at 16:18, 24 minutes ago

    Issue of Equity

  • Published on 05/29/2025 at 16:05, 38 minutes ago

    Hot Rocks Investments plc: Digital Assets Treasury Policy / Proposed Change of Name

  • Published on 05/29/2025 at 16:00, 43 minutes ago

    Director/PDMR Shareholding

  • Published on 05/29/2025 at 15:18, 1 hour 24 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated

  • Published on 05/29/2025 at 15:18, 1 hour 25 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.

View all EQS
Les Echos
  • Published on 05/28/2025 at 23:00, 17 hours 43 minutes ago

    Standstill Commitments to hold shares of the company

  • Published on 05/28/2025 at 23:00, 17 hours 43 minutes ago

    Engagements collectifs de conservation de titres de la société

  • Published on 05/28/2025 at 18:39, 22 hours 4 minutes ago

    Descriptif du programme de rachat d'actions - Mai 2025

  • Published on 05/28/2025 at 18:39, 22 hours 4 minutes ago

    Description of share-buyback program - May 2025

  • Published on 05/28/2025 at 18:34, 22 hours 8 minutes ago

    AXA a placé 1 milliard d’euros d’Obligations Restricted Tier 1 et 1 milliard d’euros d’Obligations Tier 2

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2025 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy